SRHU opens hi-tech center for Clinical Trials

Published on: October 12, 2022

Swami Rama Himalayan University opens hi-tech center for Clinical Trials
New Clinical Trials facility inaugurated at Himalayan Hospital

Clinical trials are an intrinsic part of top quality, contemporary healthcare facility, and constitute a significant step in developing new treatments to improve human health.

At Himalayan Hospital, Jolly Grant the stage has been set for clinical trials covering a rage of diseases and conditions.

HH’s Clinical Trial Centre was formally inaugurated today in the presence of experts, faculty, students and invited guests. The centre, established to conduct clinical trial studies for the development of new drugs.

Vice Chancellor Swami Rama Himalayan University, Dr Vijay Dhasmana inaugurated the centre formally today.

Clinical trials in India refer, to clinical research in which researchers test drugs and other treatments on research participants. As per rules of Government agencies (NDCTR 2019 and ICMR guidelines) it is recommended that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry – India.

Dr Nikku Yadav and Arvind, Director Somaya Research and Health Services (SRHS) assured that trials will get underway as per various government laws, and the guidelines of the Drugs Controller General of India that grants approval for conducting clinical trials in India. The trials will be held in collaboration with Somaya Research and Health Services (SRHS) LLP, which is a unique site management Organization.

SRHS provider delivers operational and administrative support services to the clinical investigator at a research site. This includes everything from handling regulatory and compliance activities to managing patient recruitment and data collection. SRHS also provides support with study start-up, monitoring, and closeout. SRHS is working with pharmaceutical companies, biotechnology companies, clinical research sites, contract research organizations (CROs), and others to enable those organizations to deliver their research in a time-efficient manner.

“The clinical trials will be conducted at the centre for multiple indications. Our doctors will be involved in the development of new drugs and also, the students of clinical research will benefit from in-house hands-on experience of clinical trials,” averred Dr Vijay Dhasmana. “The clinical trials will be conducted after the permission from DCGI India and other regulatory authorities is attained.”

Present on the occasion were Dr Vijendra Chauhan Pro Vice Chacellor SRHU, Dr Sunil Saini Director CRI, Dr Susheela Sharma Registrar SRHU, Dr Mushtaq Ahmad Director HIMS, Dr Rajendra Dobhal Director Strategies and Planning Research & Development, Dr SL Jethani CMS Himalayan Hospital, Prof CS Nautiyal, Dr Sanjay Gupta, Dr Vinita Kalra, Dr SK Verma, Dr Yashpal Singh, Dr Nikku Yadav, Dr Asha Chandola-Saklani, Dr Rajeev Bijalwan, Dr Deepshikha, Dr Vidisha, Dr Girish Gupta, Dr Suman, Dr Taruna Sharma, Dr Abha Srivastava, Dr Abhishek Kandwal, Dr Vipul Nautiyal, Prabhjot Kaur, Abhishek, Kavi and Clinical Research and Epidemiology students. The members from SRHS were Arvind Kumar, Shubham Tomar and Nidhi Yadav.

Clinical-trial-1-1.jpeg
Clinical-trial-3-2.jpeg
Clinical-trial-2-1.jpeg
   Admissions Form         

Admission Open For 2025

×
International Endowed Chair Professor

Prof Rakesh Kumar

Prof Rakesh Kumar is the Founder and President of the Breast Cancer in Young Women Foundation (USA), dedicated to vaddressing the distinct issues affecting young women with breast cancer. He also serves as the International Endowed Chair Professor at the Cancer Research Institute of the Himalayan Institute of Medical Sciences. Additionally, he holds adjunct professorships at Rutgers New Jersey Medical School and Virginia Commonwealth University.

Dr Kumar earned his Ph.D. from the All India Institute of Medical Sciences in 1984 and began his research career at Memorial Sloan Kettering Cancer Center in January 1986. From 1988 to 2017, he held various academic and leadership positions —including faculty member, tenured professor, distinguished professor, endowed chair, department chair, and research leader—at esteemed institutions such as Memorial Sloan Kettering Cancer Center in New York and the University of Texas MD Anderson Cancer Center in Houston. From 2017 to 2022, he served as the National Chair for Cancer Research for the Government of India and as a distinguished professor, continuing his innovative work in breast cancer research.

With nearly 40 years of research and professional experience, Dr. Kumar has made conceptual contributions to the field of cancer research (h-index 108, citations >50,000). He has authored over 325 peer-reviewed publications, edited or co-edited nine books, and delivered 290 invited lectures worldwide. His work has been featured on the covers of 18 major cancer journals and has been highlighted in institutional research reports of the MD Anderson Cancer Center.

A passionate educator and mentor, Dr. Kumar has guided 67 trainees throughout his career. He serves on the editorial boards of multiple leading cancer journals and has served on the editorial boards of 21 top cancer journals. His global reputation is further demonstrated by his participation in about 100 peer-review panels for cancer research funding in the US and internationally over the past 28 years.

Dr. Kumar's innovative research has earned him numerous prestigious honors, including the Hinkle Society Faculty Award at Penn State University (1994), the Dalla/Fort Worth Living Legend Faculty Achievement Award in Basic Sciences (2004), the Ranbaxy Research Award (2006), and the Lifetime Achievement Award from the American Association of Indian Scientists in Cancer Research (2013), among others. Dr. Kumar's pioneering research continues to have a profound influence on the fields of oncology and breast cancer, opening up new opportunities for biomedical scientists and trainees worldwide.